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Tank-binding kinase 1 (TBK1) is a serine/threonine
protein-kinase mediating innate antimicrobial immu-
nity. TBK1 is involved in the signaling of TLRs, RLRs,
and STING-mediated sensing of cytosolic DNA.
Stimulation of these receptors results in the acti-
vation of TBK1, which phosphorylates interferon
regulatory factor (IRF)-3. Phosphorylated IRF-3
translocates into the nucleus to initiate the transcrip-
tion of the interferon (IFN)-b gene. Here, we show that
TBK1 is activated by autophosphorylation at residue
Ser172. Structures of TBK1 bound to two inhibitors
showed that TBK1 has the IkB kinase fold with three
distinct domains: the kinase domain, the ubiquitin-
like domain, and the scaffold and dimerization
domain. However, the overall structures of the
TBK1 monomer and its dimer are different from
IKKb in the arrangements of the three domains and
in dimer formation. Phosphorylation of IRF-3 by
TBK1 in vitro results in its oligomerization, and phos-
phorylation of residue Ser386 plays a key role in
IRF-3 activation.
INTRODUCTION
Viral or bacterial infection stimulates host innate immune
responses through a wide spectrum of pattern recognition
receptors (PRRs) that recognize pathogen-associated molecular
patterns (PAMPs) such as lipids, glycans, and nucleic acids
(Barber, 2011; Keating et al., 2011; Takeuchi and Akira, 2010).
For example, Toll-like receptor 3 (TLR3) recognizes viral dou-
ble-stranded RNA at the cell surface or in the endosome and
stimulates the expression of interferons via the adaptor protein
TRIF (Oshiumi et al., 2003; Yamamoto et al., 2003). The RIG-I-
like receptors recognize viral double-stranded RNA in the
cytosol and signal through the adaptor protein MAVS/IPS-1
(Kato et al., 2011; Kawai et al., 2005; Meylan et al., 2005; Seth
et al., 2005). Microbial DNA in the cytosol activates the enzymeStructure 21, 1cGAS, which catalyzes the synthesis of cyclic-GAMP, a second-
ary messenger that regulates innate immune responses via the
adaptor protein STING (Burdette and Vance, 2013; Sun et al.,
2013; Wu et al., 2013). Stimulation of these receptors leads to
the expression of several kinds of cytokines, including type I
interferons (IFNs), such as IFN-a and IFN-b (Takeuchi and Akira,
2009). Two protein kinases, TANK-binding kinase 1 (TBK1) and
inhibitor kB kinase ε (IKKε), play critical roles in the signaling
pathway of these immunoreceptors (Fitzgerald et al., 2003;
Sharma et al., 2003). Both TBK1 and IKKε belong to the IKK fam-
ily and share about 30%sequence identity with the canonical IkB
kinases IKKa and IKKb (Ha¨cker and Karin, 2006). Engagement of
PAMPs by the PRRs leads to the recruitment and activation of
TBK1 or IKKε in a variety of signaling complexes (Ha¨cker and
Karin, 2006). Activated TBK1 and IKKε in turn phosphorylate
interferon regulatory transcription factors (IRFs) IRF-3 and
IRF-7 in the C-terminal regulatory domain (RD), resulting in olig-
omerization of these IRFs (Fitzgerald et al., 2003; Hemmi et al.,
2004; Sharma et al., 2003). Phosphorylated IRF-3 or IRF-7 then
translocate to the nucleus, bind to CREB-binding protein
(CBP)/P300, and initiate the transcription of type I interferon
genes (Lin et al., 1998; Yoneyama et al., 1998). The adaptor pro-
tein TANK, which associates with TBK1, is needed for the activa-
tion of IRF-3 and NF-kB (Cheng and Baltimore, 1996; Goncalves
et al., 2011).
Structural studies of the IKK-family protein kinases have pro-
vided important insights into the structure and function of these
kinases. The 3.6-A˚-resolution structure of the first IKK-family
kinase, Xenopus IKKb, was determined recently, revealing a
novel tripartite structure of the IKK kinase (Xu et al., 2011).
IKKb contains an N-terminal kinase domain (KD), followed by
a ubiquitin-like domain (ULD) and a scaffold and dimerization
domain (SDD) (Xu et al., 2011). IKKb forms an intimate dimer
through interactions between SDDs. The dimerization of IKKb
is not necessary for its kinase activity but is required for IKKb
activation (Xu et al., 2011). Crystal structures of the human
TBK1 KD plus ULD in an inhibited conformation and the phos-
phorylated human TBK1 KD bound to the inhibitor BX795 were
determined recently, providing insight into the mechanism of
TBK1 activation and regulation (Helgason et al., 2013; Ma
et al., 2012). While we were preparing this manuscript for sub-
mission, two reports describing the structures of human TBK1,137–1148, July 2, 2013 ª2013 Elsevier Ltd All rights reserved 1137
Figure 1. TBK1 Is Activated by Autophosphorylation
(A) Gel filtration chromatography analysis of purified mTBK1.
(B) Phosphorylation assays of wild-type mTBK1 and its mutants.
(C) TBK1 phosphorylates human IRF-3. The assay on the left used g-32P-ATP in the reaction. The band shows phosphorylated hIRF-3. The assay on the right is a
native PAGE analysis of unphosphorylated and phosphorylated hIRF-3.
(D) Inhibition of mTBK1 kinase activity by SU6668. The concentration of SU6668 used in the assay is from 8 nM to 2 mM. The bands show phosphorylated hIRF-3.
(E) GST pull-down assays of full-length and C-terminal deletion mutant of mTBK1 with TANK.
Structure
Structure of TBK1including the SDD, were published online (Larabi et al., 2013; Tu
et al., 2013).
To elucidate the structure and function of TBK1 in innate
immunity, we have expressed both full-length and truncated
forms of mouse TBK1 (mTBK1) in insect cells and determined
the structures of mTBK1 bound to two inhibitors, BX795 and
SU6668 (Clark et al., 2009; Godl et al., 2005). TBK1 kinase
assays showed that it is activated by autophosphorylation at res-
idue Ser172. In vitro phosphorylation assays of IRF-3 revealed
that TBK1 phosphorylates a distinct set of residues in IRF-3
and results in the formation of various kinds of IRF-3 oligomers
in solution. These results provide insight into the mechanism of
TBK1 activation and its roles in IRF-3 activation in innate immune
responses.
RESULTS
TBK1 Is Activated by Autophosphorylation
We have expressed glutathione S-transferase (GST) fusions of
full-length mTBK1, a C-terminal truncation form of mTBK1
(mTBK1DC, residues 1–657) and two kinase-inactive mutants
of mTBK1 (K38A and S172A in mTBK1DC constructs) in insect1138 Structure 21, 1137–1148, July 2, 2013 ª2013 Elsevier Ltd All rigcells. Gel filtration chromatography showed that all the TBK1
proteins we purified formed dimers in solution after cleavage
of the GST tag (Figure 1A). To confirm that Ser172 is the sole
phosphorylation site in autophosphorylated TBK1, we conduct-
ed in vitro phosphorylation assays of the kinase-inactive
mutants S172A and K38A (without the GST tag) using GST-
mTBK1. We found that the S172A mutant cannot autophos-
phorylate or be phosphorylated by GST-mTBK1 (Figure 1B).
The mutation K38A abolished autophosphorylation of TBK1,
but this mutant can still be phosphorylated by the wild-type
GST-mTBK1 (Figure 1B). These results demonstrated that
Ser172 is the sole autophosphorylation site of mTBK1. Next
we analyzed the kinase activity of TBK1 using full-length human
IRF-3 as a substrate. We found that TBK1 phosphorylates IRF-3
and induces the oligomerization of IRF-3 (Figure 1C). In addi-
tion, we found that mTBK1 can no longer phosphorylate IRF-3
in the presence of 1–2 mM of the inhibitor SU6668 (also known
as TSU-68), an anticancer drug under phase III clinical trials
for hepatocellular carcinoma (Kanai et al., 2011) (Figure 1D).
Furthermore, GST pull-down assays of full-length mTBK1 with
TANK showed that the two proteins interact with each other
directly. Truncation of the TANK-binding domain (TBD, residueshts reserved
Table 1. Data Collection and Refinement Statistics for TBK1
mTBK1/BX795 mTBK1/SU6668
Data Collection
Space group P3221 P3221
Cell Dimensions
a, b, c (A˚) 140.78, 140.78, 86.57 140.48, 140.48, 86.56
a,b,g () 90.0, 90.0, 120.0 90.0, 90.0, 120.0
Resolution (A˚) 3.10 (3.15–3.10)a 3.0 (3.18–3.0)
Rsym or Rmerge 6.4% (>1.0) 10.6% (>1.0)
I/sI 40.0 (1.8) 12.1 (1.7)
Completeness (%) 99.9 (100.0) 100.0 (100.0)
Redundancy 7.2 (7.5) 10.4 (10.3)
Refinement
Resolution (A˚) 3.1 3.0
No. of reflections 18240 20015










Bond lengths (A˚) 0.003 0.004
Bond angles () 0.683 0.826
Values in parentheses are for the highest-resolution shell. See also
Figure S1.
aOne crystal was used to collect each of the data sets.
Structure
Structure of TBK1658729) abolished the interaction between TBK1 and TANK
(Figure 1E). Consistent with this result, truncation of human
TBK1 in the TBD abolished the binding of another TBK1-binding
protein, NAP1 (Larabi et al., 2013). Interestingly, this truncation
does not affect TBK1 kinase activity or the phosphorylation of
IRF-3 by TBK1.
Overall Structure of Mouse TBK1
To understand the structure and function of TBK1, we deter-
mined the crystal structures of mTBK1DC (referred to as
mTBK1 hereafter) bound to two inhibitors, SU6668 and BX795,
at resolutions of 3.0 and 3.1 A˚, respectively (Table 1; see also Fig-
ure S1 available online). The refinedmodels contain 644 residues
of mTBK1. Residues 168–174 and 490–493 are not well defined
in the electron density maps. Both crystals belong to the space
group P3221 with similar unit cells. The crystallographic asym-
metric unit contains one mTBK1 molecule. The two mTBK1
molecules in the two complexes are similar, with a root-mean-
square deviation (rmsd) of 0.47 A˚ for all the Ca atoms. Two
mTBK1 molecules in the crystals form an intimate dimer related
by a crystallographic two-fold axis. The mTBK1 complex with
SU6668 will be used to describe structures (see below), due to
its slightly higher resolution and better-defined electron density
map (see also Figure S1).Structure 21, 1The overall structure of mTBK1 (Figure 2) is similar to the
recently described inactive (Protein Data Bank [PDB] ID 4IM0)
and phosphorylated (PDB ID 4IW0) human TBK1 structures
(rmsd of 1.0 A˚ compared to 4IM0 and 1.3 A˚ compared to 4IW0)
(Larabi et al., 2013; Tu et al., 2013), with some differences in
the activation loop and the C terminus tail (see also Figure S2).
Mouse TBK1 has three structurally distinct domains, the kinase
domain, the ubiquitin-like domain, and the scaffold and dimer-
ization domain (Figures 2A and 2B). The KD of mTBK1 contains
residues 1–307 and exhibits a typical bilobal protein kinase fold
(Figure 2B). The KD is followed by the ULD (residues 308–384).
The structure of the ULD in our TBK1 construct is similar to the
isolated human TBK1 ULD structure (rmsd 0.6 A˚) determined
previously (Li et al., 2012). The overall fold of the ULD is similar
to that seen in human ubiquitin, with slightly different confor-
mations in the exposed loop connecting strands b30 and b40.
The SDD of mTBK1 contains residues 385–656 (Figures 2A
and 2B). The ULD is connected to the SDD via a 22-residue
linker. Both the KD and the ULD have extensive contacts with
the SDD within the mTBK1 monomer (Figure 2B). The mTBK1
dimer resembles a pair of scissors with the KDs and the ULDs
forming the handles, and the two SDDs forming the blades (Fig-
ure 3A). The overall structure of the mTBK1 is triangular, with
dimensions of approximately 100 A˚ 3 120 A˚ 3 55 A˚. However,
unlike the case for IKKb, in the mTBK1 dimer, the KD and ULD
of one mTBK1 molecule interact with the SDD of the other
mTBK1 molecule (Figure 3). The SDDs interact with each other
through the C-terminal tip of the helical bundle (Figure 3B),
promoting the formation of the TBK1 dimer.
Interactions between the Three Domains of mTBK1
There are extensive interactions between the three domains
within an mTBK1 molecule (Figures 2C–2E). The KD interacts
with the C-terminal region of the SDD through its C-lobe, burying
a total surface area of 830 A˚2. The two loops connecting the
helices aD and aE, helix aH and strand b10 interact with the helix
a1s of the SDDand the linker between the ULD and the SDD (Fig-
ure 2C). Hydrophobic interactions between residues Ala104,
Tyr105, and Pro101 in the KD and residues Ile397, Ala417,
Val421, and Tyr424 in the SDD make major contributions to
these interactions (Figure 2C). Electrostatic interaction between
residues Glu99 and Lys416 further contributes to the interactions
between the KD and the SDD (Figure 2C). TheULD contacts both
the KD and SDD, burying 810 A˚2 and 2,200 A˚2 surface areas,
respectively, at the two interfaces. The interaction between the
KD and ULD involves two pairs of charged residues, His327
and Asp304, and Glu109 and Lys323 (Figure 2D). In addition,
hydrophobic interaction between residues Tyr325, Leu113,
and Leu273 also contributes to these interdomain interactions
(Figure 2D). Moreover, the side chain of Tyr325 forms a hydrogen
bond with the side chain of Glu109. The KD/ULD interface is
conserved in both mouse and human TBK1 structures, with or
without the SDD, indicating the rigid structure of the linker
between these two domains. The ULD binds at the middle of
the SDD helical bundle (Figure 2B). The interface between the
ULD and the SDD is extensive and hydrophobic. A large number
of hydrophobic residues, such as Phe314, Leu316, Met319,
Ala321, Ile353, and Phe380 from the ULD and Leu438,
Met439, Leu387, Met439, Tyr435, Trp445, Leu449, Phe612,137–1148, July 2, 2013 ª2013 Elsevier Ltd All rights reserved 1139
Figure 2. Crystal Structure of Mouse TBK1
(A) Domain organization of mTBK1, showing the
boundaries of the KD, ULD, SDD, and TBD. The
construct used for crystallization is truncated at
the C terminus of the SDD at residue Thr657.
(B) Ribbon representation of the structure of the
mTBK1monomer rainbow colored from blue at the
N-terminus to red at the C terminus. The inhibitor
SU6668 is shown by the yellow stick model.
(C) Close-up view of the interface between the KD
(blue) and the SDD (red). Residues mediating the
interactions between the two domains are shown
by the stick models.
(D) Interactions between the KD (blue) and the ULD
(green).
(E) Close-up view of the interface between the ULD
(green) and the SDD (red).
See also Figure S1.
Structure
Structure of TBK1andMet620 from the SDD, are involved in these interactions (Fig-
ure 2E). Electrostatic interactions between Glu351 and Arg627
and between Arg358 and Asp453 make additional contributions
to the ULD/SDD interaction (Figure 2E).
Structure of the mTBK1 Scaffold and Dimerization
Domain
The SDD ofmTBK1 forms a long twisted helical bundle110 A˚ in
length (Figure 2B). The two long continuous helices a1s and a4s
contain 77 and 70 residues, respectively. The C-terminal 30 res-
idues of helix a1s make major contributions to the TBK1 dimer
formation (Figures 3A and 3B). The third helix is broken into
two segments of 24 (a2s) and 31 (a3s) residues connected by
a long loop of 29 residues (Figure 2B). Although the overall struc-
ture of mTBK1 is similar to that of IKKb, the organization of the
three domains in mTBK1 is dramatically different from that of
IKKb (Figure 4). When the structurally conserved kinase domains
of mTBK1 and IKKb are superimposed, the positioning of the
ULDs and SDDs are obviously different in the two structures (Fig-
ure 4A). As reflected by the low sequence identity between the
SDDs, the structures of the helical bundle in mTBK1 and IKKb1140 Structure 21, 1137–1148, July 2, 2013 ª2013 Elsevier Ltd All rights reservedare quite different (rmsd of 4.5 A˚ for 151
Ca atoms). Superposition of the two
SDDs showed that only the third helices
of the two structures match each other
(see also Figure S3). The other helices,
especially the first helices in the SDDs,
are positioned differently in the two struc-
tures. These structural differences may
contribute to the different functions of
the two kinases in innate immunity, such
as substrate specificity.
Molecular Interactions in the TBK1
Dimer
Both human TBK1 KD and human TBK1
KD-ULD are monomers in solution (Ma
et al., 2012). In contrast, mTBK1 with the
SDD forms an intimate dimer in solution
and in the crystal, suggesting that theSDD-mediated dimer is likely functionally relevant. Small-angle
X-ray scattering (SAXS) and electron microscopy (EM) analysis
of similar human TBK1 constructs confirmed this hypothesis
(Larabi et al., 2013; Tu et al., 2013). All three domains of
mTBK1 are involved in the dimer formation (Figure 3). The total
buried surface area at the mTBK1 dimer interface is 4,300 A˚2,
with the SDDs contributing 1,800 A˚2, the ULDs contributing
1,200 A˚2, and the KDs contributing 1,500 A˚2. Electrostatic
and hydrophobic interactions between the SDDs make major
contributions to the dimer interface (Figure 3B). Four pairs of
charged residues between Glu456 and His459, Asp649, and
Lys479 from both TBK1 molecules in the dimer, are observed
at the interface between the SDDs (Figure 3B). In addition, five
pairs of hydrophobic residues, including Leu458, Val481,
Phe470, Ile466, and Tyr482 from both of the SDDs, are buried
at the SDD interface (Figure 3B). The kinase domain interacts
with the neighboring SDD through two loops connecting strands
b3 and b4 and strands b7 and b8 (Figure 3C). Six pairs of charged
residues, including Asp148 and Arg547, Glu147 and Lys596, and
Asp33 and Lys589 from both TBK1 molecules in the dimer, are
observed at the KD/SDD interface across the dimer (Figure 3C).
Figure 3. Structure of the mTBK1 Dimer
(A) Ribbon representations of two views of the
mTBK1 dimer. The KDs are colored blue and light
blue, the ULDs green and cyan, and the SDDs red
and brown.
(B) Interactions between the SDDs in the mTBK1
dimer. Residues at the SDD interface are shown by
the pink and the yellow stick models. For clarity,
only one set of residues is labeled in the symmet-
rical dimer.
(C) Interactions between the KD (blue) and the SDD
(brown) in the mTBK1 dimer.
(D) Interactions between the ULD (green) and the
SDD (brown) in the mTBK1 dimer.
Structure
Structure of TBK1In addition, three hydrophobic residues, Val554, Phe585, and
Ile582, mediate van der Waals contacts between the KD and
the SDD (Figure 3C). The extensive interactions between the
KD and the SDD, both within the mTBK1 monomer and across
the dimer interface, likely contribute to the overall structural rigid-
ity of mTBK1. In addition, four pairs of charged residues, Glu355
and Arg444 and Arg357 and Asp452 from both TBK1 molecules
in the dimer, mediate the interactions between the ULDs and the
SDDs in the mTBK1 dimer (Figure 3D). The bulky side chains of
Tyr354 and Trp455 buried at the dimer interface also contribute
to the ULD/SDD interactions (Figure 3D). Mutations of residues
at the dimer interface that disrupted the dimerization of TBK1
reduce the kinase activity and the autophosphorylation of human
TBK1 (Larabi et al., 2013; Tu et al., 2013). In contrast to mTBK1,
the dimer interaction between IKKb is mediated exclusively by
the SDDs (buried surface of 3,200 A˚2), with extensive contacts
at both ends of the SDDs (Figure 4C). Hydrophobic interactions
near the C-terminal of the SDDs make major contributions to the
IKKb dimer formation. In addition, electrostatic interactions near
the N-terminal of the SDDs make minor contributions to the
dimer interface.
Structure of the mTBK1 Kinase Domain
The structure of the mTBK1 KD (Figure 5A) is similar to that of the
previously determined human TBK1KD in the inactive conforma-
tion (rmsd 1.46 A˚ for 257 Ca atoms; Figure 5B). The overall struc-
ture of mTBK1 KD is also very similar to the phosphorylatedStructure 21, 1137–1148, July 2, 2013 ªhuman TBK1 KD (rmsd 1.28 A˚ for 259
Ca atoms; Figure 5C) (Ma et al., 2012).
The major structural differences between
mTBK1 KD and the inactive or active
human TBK1 KD are obvious only at the
activation loops and the aC helices (Fig-
ures 5B and 5C). It seems that the kinase
domains of TBK1, excluding the activa-
tion loop and the aC helix, are quite
rigid even in the absence of the SDD.
The backbone structures of the kinase
domain are not affected by interactions
with the ULD or the SDD, or by phosphor-
ylation at Ser172 (Figures 5B and 5C).
Although the activation-loop structure of
mTBK1 is quite different from that in
the human TBK1 KD-ULD structure (Fig-ure 5B), both form a domain-swapped dimer in the crystals,
interacting with a neighboring kinase domain using the same
set of residues (residues 178–184 in mTBK1) containing the
HPD motif (see also Figure S4). These residues are well defined
in the electron density map, but the flanking residues are poorly
defined in themTBK1 structure, reflecting the structural flexibility
of the activation loop in the inactive kinases. In contrast, the HPD
motif was modeled as part of the KD within a TBK1 monomer in
the inactive human TBK1 structures (see also Figure S2) (Larabi
et al., 2013; Tu et al., 2013). Phosphorylation of human TBK1 at
residue Ser172 results in refolding of the activation loop (Fig-
ure 5C). Interactions between p-Ser172 and three positively
charged residues, Arg54, Arg134, and Arg163, stabilize the
active conformation of the activation loop. Strikingly, residues
178–184 around the HPDmotif within the active kinase displaced
these residues from a neighboring kinase to form the active
conformation of TBK1 (Figure 5C), suggesting that the interac-
tions between residues 178–184 and the KD in the inactive ki-
nase may play an inhibitory role in the domain-swapped dimer.
The same short polypeptide also plays a key role in maintaining
the active conformation of TBK1.
To understand the roles of the SDD in TBK1, we generated a
molecular model of active mTBK1 by superpositioning the crys-
tal structure of phosphorylated human TBK1 KD (PDB ID 4EUU)
onto the structure of mTBK1. The backbone structure of the
model is very close (rmsd 1.0 A˚) to that of the 4.0-A˚-resolution
structure of phosphorylated human TBK1, confirming that this2013 Elsevier Ltd All rights reserved 1141
Figure 4. Mouse TBK1 Exhibits Distinct
Domain Organization Compared to the
Canonical IkB Kinase
(A) Superposition of mTBK1 (blue, green, and red)
and Xenopus IKKb (yellow) structures via the kinase
domains.
(B) Structure of the mTBK1 dimer viewed along the
SDD helical bundles (red and brown). The C-termini
of the SDDs point away from the reader.
(C) Structure of Xenopus IKKb in the same orien-
tation as for mTBK1 in (B), showing the different
arrangement of its KD and ULD relative to the SDD.
See also Figure S3.
Structure
Structure of TBK1model is valid for structural analysis (Larabi et al., 2013). To
probe the substrate-binding site and the active site of TBK1 in
this model, we superimposed the protein kinase A (PKA) sub-
strate complex structure (PDB ID 1ATP) onto this model (Zheng
et al., 1993). The model indicates that mTBK1 likely binds the
substrate at a deep groove between the KD and the SDD (Fig-
ure 5D; see also Figure S5). It is likely that the N-terminal section
of helix a1 and the linker between the ULD and the SDD are
involved in substrate recognition by TBK1 (Figure 5D; see also
Figure S5). It has been suggested that the corresponding regions
of IKKb are likely involved in substrate recognition as well (Xu
et al., 2011).
We observed that the two inhibitors of TBK1, BX795 and
SU6668, bind to the ATP-binding pocket between the N-lobe
and the C-lobe of the kinase domains (Figure 5E). The aromatic
rings of the two inhibitors occupy the binding pocket for the
adenine base of ATP (Figure 5E). The inhibitors interact with
TBK1 mainly through hydrophobic interactions and hydrogen
bonds. Based on the structure of SU6668 bound to TBK1, it is
possible to improve the specificity and affinity of this family of
compounds to TBK1. The methyl group attached to C5 could
be replaced by a hydrophilic hydroxyl or amine group that may
form additional hydrogen bondswith the nearby carbonyl groups
of residues Cys89 and Pro90. A hydroxyl group or amine group
could be attached to C15 to form a hydrogen bond with the
carbonyl of Glu87. It will also be favorable to replace the methyl
group connected to C7 with a hydroxyl group that may form a
hydrogen bond with the amine group of Gly16.
The Mechanism of IRF-3 Activation by TBK1
To elucidate the mechanism of IRF-3 activation by TBK1, we
conducted in vitro phosphorylation assays of human IRF-31142 Structure 21, 1137–1148, July 2, 2013 ª2013 Elsevier Ltd All rights reserved(hIRF-3) using purified mTBK1. We found
that hIRF-3 is potently phosphorylated
by mTBK1 without the need of any addi-
tional proteins. Gel filtration chromato-
graphy analysis showed that phosphory-
lation of IRF-3 induced oligomerization of
the protein (Figure 6A). The estimated
mass of the hIRF-3 oligomer is about 300
kD (Figure 6A), which is much larger than
an IRF-3 dimer (theoretical mass 95 kD).
The phosphorylated hIRF-3 peak is broad
and unsymmetrical (Figure 6A), indicatingthe existence of multiple species in the samples. In addition,
phosphorylation of the hIRF-3 regulatory domain (RD) by
mTBK1 also induced oligomerization of the protein (Figure 6B),
demonstrating that the phosphorylated IRF-3 RD mediates olig-
omerization of IRF-3. The estimatedmolecular mass of the phos-
phorylated hIRF-3 RD is about 130 kD, which is much larger than
a dimer of the RD (theoretical mass 65 kD). This further supports
that phosphorylation of IRF-3 by TBK1 induces oligomerization
of the protein.
To determine the oligomerization state of the phosphorylated
IRF-3, we analyzed the phosphorylated hIRF-3 by analytical
ultracentrifugation (AUC; Figures 6C–6F). Sedimentation velocity
experiments revealed that native hIRF-3 sedimented predomi-
nantly as a single monomeric species with a frictional ratio
of 1.5, consistent with a mildly elongated protein (Figures 6C
and 6E). Upon phosphorylation, the hIRF-3 monomeric peak
shifted to a combination of compact, faster-sedimenting species
and a series of higher-order oligomers (Figures 6D and 6F). The
compact species show very low frictional coefficients near 1.0
(which corresponds to an ideal sphere), with estimated masses
consistent with monomer and dimer species that are in
exchange over the time course of the sedimentation experiment.
Thus, phosphorylation induces a conformational collapse of the
hIRF-3 monomer into nearly-spherical monomeric and dimeric
species. Furthermore, the phosphorylated hIRF-3 formed
several higher-order oligomers, including a highly elongated
putative tetramer with a frictional ratio >3, and a series of fiber-
like oligomers with estimated masses ranging from a 13-mer to
a 32-mer (Figures 6D and 6F). We report these data as evidence
of the significant conformational change in full-length hIRF-3 and
the formation of highly elongated oligomers and fiber-like spe-
cies upon phosphorylation by TBK1. It is obvious from this study
Figure 5. Structure of the mTBK1 Kinase
Domain
(A) Ribbon representation of the structure of
mTBK1 KD bound to the inhibitor SU6668. The KD
is rainbow colored from blue at the N-terminus to
green at the C terminus. The inhibitor SU6668 is
shown by the yellow stick model.
(B) Comparison of the mouse (blue to green) and
human (magenta) TBK1 KD structures in the inac-
tive conformations. The human TBK1 KD structure
was determined without the SDD.
(C) Comparison of the mouse TBK1 KD structure
with the phosphorylated human TBK1 KD struc-
ture. The human TBK1 KD structure was deter-
mined without the ULD and the SDD. Phosphory-
lated Ser172 in the human TBK1 KD is shown by
the red stick model.
(D) Molecular model of phosphorylated mTBK1.
The model was generated by superimposing the
phosphorylated human TBK1 KD (cyan ribbons)
onto the KD of the mTBK1 structure. ATP (gray
stick model) and the substrate of PKA (yellow
space-filling model) were introduced into the
model by superimposing the PKA structure onto
the TBK1 KD structure. The mTBK1 SDD is shown
by the gray space-filling model, with the C terminus
of the SDD pointing away from the reader.
(E) The SU6668 andBX795 binding sites ofmTBK1.
TBK1 is shown by the cyan and light blue surface
representations. The inhibitors are shown by the
yellow stick models. ATP was introduced to the
mTBK1 structure by superimposing the PKA/ATP
complex structure onto the mTBK1 KD.
See also Figures S4 and S5.
Structure
Structure of TBK1that phosphorylation of IRF-3 induced the oligomerization,
instead of merely dimerization, of IRF-3. To investigate which
oligomer of IRF-3 might be functional, we expressed the IRF-3
binding domain of CBP, purified the phosphorylated IRF-3 RD
bound to CBP, and analyzed the complex by gel filtration chro-
matography. The IRF-3 RD and CBP complex is homogenous
and shows a symmetrical peak with an estimated mass of 98
kD (see also Figure S6). Based on this result, it is likely that the
IRF-3 RD dimer or trimer associates with CBP. As no higher-
order complex between CBP and IRF-3 was observed, it is likely
that phosphorylated IRF-3 is in an equilibrium of various oligo-
mers, but that only one type among these oligomers binds CBP.
To identify the TBK1 phosphorylation sites of IRF-3, we sepa-
rated the phosphorylated hIRF-3 from mTBK1 by SDS-PAGE,
then analyzed the phosphorylated hIRF-3 by liquid chro-
matography-tandem mass spectrometry (LC-MS/MS) afterStructure 21, 1137–1148, July 2, 2013trypsin digestion. Over 80% of the
IRF-3 sequence was covered in this
analysis, which included the complete
RD (see also Figure S7). Phosphorylation
at residues Thr3, Ser14, Thr75, and
Ser97 was observed in the N-terminal
DNA binding domain of hIRF-3 (see
also Figure S7). Phosphorylation of
Thr180, Ser188, Thr237, Thr244, Thr253,
Ser386, Ser398, Thr404, and Ser427 wasobserved in the hIRF-3 RD (see also Figure S7). The MS analysis
clearly identified Ser386, Ser398, and Thr404 as the primary
TBK1 phosphorylation sites in the RD of hIRF-3 (Figure 6G). To
examine the roles of these phosphorylated residues in IRF-3
activation, we generated five mutants of hIRF-3 based on the
phosphorylation sites identified in our MS analysis and previous
reports (Suhara et al., 2000; Takahasi et al., 2010; Yoneyama
et al., 2002). We purified all the hIRF-3 mutants to homogeneity
and conducted in vitro phosphorylation assays using purified
mTBK1. Consistent with results from previous studies, we found
thatmutationsofSer386 toalanine abolishedhIRF-3dimerization
after phosphorylation (Figure 6H). Mutations of other residues,
such as Ser396, Ser398, Ser402 individually, or Thr404 together
with Ser405, reduced the rate of IRF-3 oligomer formation (Fig-
ure 6H). These results showed that the phosphorylation of
Ser386 in IRF-3 is necessary for the activation of IRF-3 by TBK1.ª2013 Elsevier Ltd All rights reserved 1143
Figure 6. Phosphorylation of IRF-3 by TBK1
Induces the Oligomerization of IRF-3
(A) Gel filtration chromatography analysis of phos-
phorylated full-length hIRF-3.
(B) Gel filtration chromatography analysis of phos-
phorylated hIRF-3 RD.
(C) Analytical ultracentrifugation analysis of un-
phosphorylated IRF-3, shown as a three-dimen-
sional shape-and-size distribution plot. Higher
values of f/f0 correspond to elongated species; an
f/f0 value of 1.0 corresponds to an ideal sphere.
(D) Three-dimensional shape-and-size distribution
plot for phosphorylated IRF-3, revealing a combi-
nation of nearly spherical species (f/f0 near 1.0) and a
series of elongated oligomeric forms.
(E and F) Two-dimensional representations of the
plots in (C) and (D), respectively, with the major
peaks identified based on frictional ratio and pre-
dicted mass.
(G) Phosphorylation sites in the RD of hIRF-3 iden-
tified by LC-MS/MS.
(H) Mutations of hIRF-3 at the TBK1 phosphorylation
sites affect phosphorylation- induced oligomeriza-
tion of IRF-3. Wild-type and mutants of hIRF-3 were
phosphorylated with mTBK1. The phosphorylated
samples were analyzed by native PAGE.
See also Figures S6 and S7.
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Structure of TBK1DISCUSSION
We have conducted comprehensive biochemical and struc-
tural characterizations of mTBK1. Our results suggest that
TBK1 is activated by autophosphorylation in trans at residue
Ser172. Although the truncation of TBD does not affect TBK1
kinase activity or the phosphorylation of IRF-3, the truncated
TBK1 failed to associate with the adaptor protein TANK. In
addition, the structures of TBK1 bound to the inhibitors1144 Structure 21, 1137–1148, July 2, 2013 ª2013 Elsevier Ltd All rights reservedrevealed additional structure features of
TBK1. Although TBK1 contains three
domains, similar to IKKb (Xu et al., 2011),
the relative orientation of the three do-
mains and the way they interact with
each other are dramatically different in
TBK1 and IKKb. The structure of the
SDDs of TBK1 and IKKb are rather
different. Furthermore, the in vitro phos-
phorylation experiments showed that
TBK1 phosphorylates IRF-3 directly and
induces oligomerization of IRF-3. Mass
spectrometry analysis of IRF-3 phosphor-
ylated by TBK1 identified a distinct set of
residues in both the DNA-binding domain
and the C-terminal RD of TBK1. Interest-
ingly, our mutagenesis analyses show
that phosphorylation of residue Ser386 is
critical for the activation of IRF-3 by
TBK1. These results provided important
structural insights into the biological func-
tions of TBK1 in mediating the signaling of
innate immune receptors.The structures of human TBK1 KD + ULD in the inactive
conformation and the phosphorylated KD provided insight into
the mechanism of TBK1 activation and inhibition (Ma et al.,
2012). Our structural study of nearly full-length TBK1 provided
additional insight into the structure and function of TBK1 (Fig-
ure 2B). The structure showed that mTBK1 forms an intimate
dimer through extensive interactions between the SDDs, and
between the KDs and ULDs and the SDDs (Figure 3). The exten-
sive interactions between the three domains within the TBK1
Structure
Structure of TBK1monomer and dimer indicate that the TBK1 kinase domain has a
relatively rigid structure; thus, it is unlikely that two kinase
domains within the TBK1 dimer would interact with each other
or phosphorylate each other. Consistent with this observation,
only a small fraction of TBK1 is phosphorylated when purified
from the insect cells. Perhaps this is a mechanism to prevent
the premature activation of the enzyme without the stimulation
of innate immune receptors. In contrast, TBK1 constructs
without the SDD are extensively phosphorylated even when
they were coexpressed with phosphatase (Ma et al., 2012), indi-
cating that the SDD is important in regulating the activation of
TBK1. As shown by the domain-swapped dimer structure of
TBK1 observed in the crystals (see also Figure S4), it is most
likely that TBK1 autophosphorylates in trans, which is consis-
tent with the model proposed previously based on the structural
studies of human TBK1 without the SDD (Ma et al., 2012). Since
TBK1 with truncations in the SDD is not functional in cells (Gon-
calves et al., 2011), it is obvious that the SDD plays a critical role
in the function of TBK1. The C-terminal region of TBK1 is
needed to interact with various kinds of adaptor proteins such
as TANK and NAP1 (Goncalves et al., 2011). These adaptor
proteins likely mediate the recruitment of TBK1 to distinct
signaling complexes (Goncalves et al., 2011). Consistent with
these implications, we found that truncation of the TBD of
TBK1 disrupted its interaction with TANK. Our structural anal-
ysis indicated that the SDD likely has additional functions. For
example, TBK1 may bind its substrate at a deep groove
between the SDD and KD, so the SDD may also contribute to
substrate recognition by TBK1.
Another important question about the function of TBK1 is how
TBK1 activates IRF-3 in response to microbial infection. An
induced proximity model for TBK1 activation has been proposed
previously (Ma et al., 2012). This model suggests that stimulation
of immunoreceptors such as TLRs, RLRs, and STING results in
the recruitment of TBK1 and IRF-3 to the signaling complex,
and the induced proximity of TBK1 leads to the activation of
the kinase and subsequent phosphorylation of IRF-3 (Ma et al.,
2012). Our in vitro IRF-3 phosphorylation experiments support
this model. We found that at sufficiently high concentrations,
TBK1 autophosphorylates and activates IRF-3 without the
need of any additional factors (Figures 1B and 1C). Consistent
with these results, overexpression of TBK1 in cells induces the
expression of IFN-b (Fitzgerald et al., 2003). The conformation
change of STING upon ligand binding likely promotes the recruit-
ment of TBK1 to the signaling complex (Huang et al., 2012). In
addition, K63-linked ubiquitination of TBK1 at residues Lys30
and Lys401 seems also required for TBK1 activation and
signaling (Tu et al., 2013). The polyubiquitin chains on these
residues likely play a role in bringing the TBK1 dimers close to
each other for autophosphorylation (Larabi et al., 2013; Tu
et al., 2013).
Our mass spectrometric analysis of in vitro phosphorylated
IRF-3 by TBK1 showed that Ser386, Ser398, and Thr404 in
the RD of IRF-3 are key sites of phosphorylation by TBK1 (Fig-
ure 6G; see also Figure S6) that are critical for the phosphory-
lation-induced oligomerization of IRF-3. A comparison of phos-
phorylation sites identified previously with our data indicates
that TBK1 and IKKε phosphorylate a distinct but overlapping
set of residues (Fujii et al., 2010; Takahasi et al., 2010). BothStructure 21, 1TBK1 and IKKε specifically phosphorylate Ser386 but selec-
tively phosphorylate other residues in the RD of IRF-3. In
previous studies, both sets of residues were observed in phos-
phorylated IRF-3 (Lin et al., 1998; Yoneyama et al., 1998). It is
likely that both TBK1 and IKKε are involved in the activation of
IRF-3 and that these two kinases may not be functionally
redundant.
Analytical ultracentrifugation analysis of in vitro phosphory-
lated IRF-3 showed that phosphorylation of IRF-3 by TBK1
induces a conformational change and results in the formation
of dimers, tetramers, and oligomers of IRF-3 (Figures 6C–6F).
Consistent with the AUC results, gel filtration chromatography
of phosphorylated IRF-3 shows a broad peak with an estimated
size much larger than an IRF-3 dimer (Figures 6A and 6B).
These different forms of oligomers likely resulted from different
levels of phosphorylation. Consistent with this, ion-exchange
chromatography showed that IRF-3 RD coexpressed with
IKKε also forms various kinds of monomers, dimers, and oligo-
mers at different levels of phosphorylation (Takahasi et al.,
2010). It is also possible that fully phosphorylated IRF-3 exists
in an equilibrium of these oligomers. It is likely that the oligo-
mers of IRF-3 are required for transcription initiation due to their
increased affinity for DNA. Since TBK1 and IKKε may play
complementary roles in IRF-3 activation, it will be interesting
to test what happens when IRF-3 is phosphorylated by both
TBK1 and IKKε.
There are still a number of unresolved questions concerning
the structure and function of TBK1. For example, it is not clear
how TBK1 mediates distinct signaling events from different
receptors. Interactions of TBK1 with various kinds of adaptor
proteins may contribute to its roles in different signaling events.
TBK1 phosphorylates a wide range of substrates involved in
immunity and other cellular functions (Barbie et al., 2009; Ou
et al., 2011; Pilli et al., 2012; Wild et al., 2011; Xie et al.,
2011), but it is not clear how TBK1 achieves such a wide
range of substrate specificity. Structures of phosphorylated
TBK1 in complex with various substrates or peptides from
these substrates will provide insight regarding these important
questions.
TBK1 is an important therapeutic target for antimicrobial and
anticancer agents. The crystal structures of mTBK1 bound to
the two inhibitors provided a structural basis for designing novel
inhibitors of TBK1. Although both BX795 and SU6668 bind at the
ATP binding site, they interact with TBK1 in different ways.
SU6668 has additional contacts with TBK1 on the opposite
side of the triphosphate group, whereas BX795 has additional
contacts near the triphosphate binding sites (Figure 5E). New
inhibitors can be designed based on these two structures to
improve their specificity for TBK1. Moreover, the HPD-motif
binding site may serve as another target for drug design. This
motif interacts specifically with inactive TBK1 in the domain-
swapped dimer and likely plays a role in suppressing the auto-
phosphorylation of TBK1. Inhibitors based on this structure are
likely highly specific for TBK1. The potential substrate-binding
site between the KD and the SDD can also be a target for drug
design. A short helical peptide is likely to bind to this site and
block the access of the substrate. Therefore, our work may
have important implications in designing novel antimicrobial or
anticancer agents targeting TBK1.137–1148, July 2, 2013 ª2013 Elsevier Ltd All rights reserved 1145
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Structure of TBK1EXPERIMENTAL PROCEDURES
Protein Expression and Purification
Full-length and C-terminal truncated (residues 1–657) mouse TBK1 were
cloned into the pAcGHLTc baculovirus transfer vector. The vector contains a
GST tag and a 6xHis tag upstream of the multiple cloning sites. The plasmids
were transfected with Baculo-Gold bright linearized baculovirus DNA (BD
Biosciences) into sf9 insect cells to generate recombinant baculovirus. The
recombinant viruses were amplified for at least two rounds before being
used for large-scale protein expression. To express the proteins, the insect
cells were infected with the recombinant baculovirus in serum-free media
(Thermo Scientific). The cells were cultured at 27C and harvested 60 hr after
infection. The selenomethionine (Se-Met)-substituted mTBK1DC S172A was
expressed in sf9 cells. These cells were initially grown in serum-free insect
cell medium (Thermo Scientific). The viral stock was added to the cells at a
density of 2.5 3 106 cells/ml, and the infected cells were harvested by centri-
fugation and resuspended in the ESF921methionine-free medium (Expression
Systems) 24 hr after infection. Se-Met (Arcos Organics) was added at 100mg/l
of culture at 12 hr and again at 36 hr after medium change. The cells were
harvested 72 hr after infection. The cells were lysed in the lysis buffer (0.2 M
Tris-HCl, 150 mM NaCl, 1 mM PMSF, 1% NP-40 [pH 8.0]). The recombinant
proteins in the lysate supernatant were purified by nickel affinity chromatog-
raphy (batch method) followed by gel filtration chromatography. For crystalli-
zation or other assays, the GST-His tag was cleaved by thrombin before gel
filtration chromatography.
Human IRF-3 (hIRF-3), human IRF-3 RD (residues 189–427, hIRF-3C),
mouse TANK (mTANK), and human CBP (residues 2066–2111) were cloned
into vector pET28-SUMO and expressed in Escherichia coli BL21(DE3) cells
at 15C. The recombinant proteins were purified by nickel affinity chromatog-
raphy followed by gel filtration chromatography. The 6xHis-SUMO tag was
cleaved using SUMO protease before gel filtration chromatography. All these
proteins were eluted from the gel filtration column using a buffer containing
20 mM Tris-HCl, 150 mM NaCl (pH7.5) (buffer A). The samples were concen-
trated and snap frozen in liquid nitrogen and stored at 80C. All the mutants
of TBK1 and IRF-3 were generated using theQuickChange site-directedmuta-
genesis Kit (Stratagene) according to the manufacturer’s protocol. The mutant
proteins were purified the same way as the wild-type proteins.
Protein Kinase Assays
The in vitro kinase assay was performed as described previously with some
modifications (Shu et al., 2012). For TBK1 autophosphorylation assays, in
each 30 ml kinase assay reaction, 3 mg mTBK1 or mutants were incubated
with or without 1 mg GST-mTBK1 in a buffer consisting of 20 mM HEPES
(pH 7.5), 100 mM NaCl, 10 mM MgCl2, 2 mM dithiothreitol (DTT), 100 mM
ATP, and 0.5 ml [g-32P] ATP for 2 hr at room temperature. To analyze TBK1
inhibition by SU6668, in each 30 ml kinase assay reaction, 100 ng prephos-
phorylated mTBK1DC was incubated with a serial dilution (2-fold) of SU6668
in a buffer consisting of 10 mg hIRF-3, 20 mM HEPES (pH 7.5), 100 mM
NaCl, 10 mM MgCl2, 2 mM DTT, 100 mM ATP, and 0.5 ml [g-
32P] ATP for 2 hr
at room temperature. The phosphorylated samples were resolved by SDS-
PAGE using 10% gel and imaged using a storage phosphor imaging system.
For IRF-3 gel shift assays, each 50 ml kinase assay reaction contains 36 mg
hIRF-3 or its mutants and incubated with 6 mg prephosphorylated mTBK1 in
a buffer containing 20 mM HEPES (pH 7.5), 100 mM NaCl, 10 mM MgCl2,
2 mM DTT, and 5 mM ATP for 40 min at room temperature. Phosphoryla-
tion-induced oligomerization of wild-type hIRF-3 or its mutants was examined
by native PAGE using 10% gels.
GST Pull-Down Assays
In the GST pull-down assays, 100 ml recombinant GST-mTBK1 or GST-
mTBK1DC with or without purified TANK was incubated with 40 ml gluta-
thione-Sepharose beads (GE Healthcare) and incubated at 4C for 1 hr. The
beads were washed four times with 200 ml of PBS buffer, boiled in SDS-
PAGE loading buffer, and analyzed by SDS-PAGE using 10% gels.
Crystallization, Data Collection, and Structure Determination
Mouse TBK1 is partially phosphorylated when purified from insect cells and
does not crystallize. To generate homogeneous sample for crystallization,1146 Structure 21, 1137–1148, July 2, 2013 ª2013 Elsevier Ltd All rigwe treated mTBK1 with l phosphatase and crystallized it in complex with
BX795. The kinase-inactive S172A mutant of mTBK1 was generated later on
and crystallized under conditions similar to those used for the dephosphory-
lated protein. To crystalize mTBK1, native or Se-Met labeled mTBK1DC
S172A was concentrated to 10 mg/ml, and the inhibitors were added to
the samples at a concentration of 0.15 mM. The proteins were crystallized
by hanging-drop vapor-diffusion method at 4C over a reservoir containing
0.1 M sodium citrate, 10%14% isopropanol and 0.1 M HEPES buffer
(pH 8.0). Large single crystals grew in about 2 weeks. The crystals were frozen
in liquid nitrogen in a cryo-buffer containing 30% ethylene glycol and 10%
PEG400 in the mother liquor. The diffraction data were collected at the
Advance Light Source, beamlines 5.1 and 5.2. The BX795 complex data
were processed with the HKL2000 package (Otwinowski and Minor, 1997).
The SU6668 complex data were processed withMosflm and scaled with Scala
in the CCP4 package (Winn et al., 2011). Statistics of data collection are shown
in Table 1.
The structure of the mTBK1/BX795 complex was determined by molecular
replacement using the kinase and ubiquitin-like domains of human TBK1 (PDB
ID 1EUT) and the C-terminal domain of Xenopus IKKb (PDB ID 3QA8) as search
models with Phaser in the Phenix package (Adams et al., 2010). The C-terminal
domain of mTBK1 was completely remodeled due to low sequence homology
and structural similarity with IKKb. The amino acid sequence of mTBK1 was
confirmed by an anomalous difference map (Dano-Fc map) from a Se-Met
derivative crystal. Thirteen peaks (>4.8s) were observed in the map, of which
12 correspond to the Se sites and one corresponds to the iodine atom in
BX795. The structures were refined using the Phenix package (Adams et al.,
2010). The mTBK1/SU6668 complex structure was solved by molecular
replacement using the refinedmTBK1/BX795 complex structure as the search
model. After remodeling in O (Jones and Kjeldgaard, 1997), the structure was
refined with the Phenix package. Statistics of structural refinement are shown
in Table 1. Buried surface area andmolecular contacts were evaluatedwith the
CNS 1.3 package (Bru¨nger et al., 1998). Comparison of the structures was
carried out with the program Superpose in the CCP4 package. The graphics
software Coot (Emsley et al., 2010) was used extensively during remodeling
and refinement. All structural figures were generated with PyMol.
Gel Filtration Chromatography of Phosphorylated IRF-3
Human IRF-3 at 1 mg/ml concentration was incubated for 16 hr at 27C with
0.05 mg/ml GST-mTBK1 in a buffer containing 20 mM HEPES (pH 7.5),
100mMNaCl, 10mMMgCl2, 0.1mM sodium vanadate, 5mMsodium fluoride,
5 mMDTT, and 5 mMATP. The phosphorylated IRF-3 was purified on a Hiload
16/60 superdex200 column (GE Healthcare) eluted with buffer A. The purified
sample was analyzed on a Superdex200 (10/300 GL) column (GE Healthcare)
eluted with buffer A. The column was calibrated with a set of protein standards
for gel filtration chromatography (Bio-Rad) to ensure accurate estimation of the
molecular weight of the proteins.
Analytical Ultracentrifugation Analysis of IRF-3
AUC analyses of sedimentation velocity were conducted using a Beckman
ProteomeLab XL-I with samples of full-length hIRF-3 in both native and phos-
phorylated states, each in a buffer of 20 mM Tris-HCl (pH 7.5), 150 mM NaCl,
and 5 mM b-mercaptoethanol. Samples were spun overnight at 44,000 rpm in
an An-60Ti rotor maintained at 10C, and data were collected using absor-
bance optics. Raw sedimentation data were deconvoluted into sedimentation
coefficient distributions using both c(s) and c(s,f/f0) approaches in the program
Sedfit version 12.0c (Brown and Schuck, 2006). Data were examined at both
95% and 67% confidence intervals in the c(s) and c(s,f/f0) analysis. Both ana-
lyses revealed similar predicted molecular masses for the various species
observed. The 67% confidence interval data better illustrate the component
species in solution after hIRF-3 phosphorylation. Values for buffer density
and viscosity and partial specific volume of hIRF-3 were calculated using
Sednterp version 1.09.
Mass Spectrometry of Phosphorylated IRF-3 and TBK1
The proteins in the SDS-PAGE gel bands were reduced with DTT to break the
disulfide bond, and cysteine residues were alkylated by iodoacetamide to
allow the recovery of Cys-containing peptides. The gel bands were washed,
dried down in a speed vacuum, and rehydrated with a buffer containing trypsinhts reserved
Structure
Structure of TBK1to allow trypsin to enter the gel. The peptide samples were loaded on a nano-
scale capillary reverse-phase C18 column by a high-performance liquid chro-
matography system (Waters ACQUITY UPLC), and eluted by a gradient
(30 min). The eluted peptides were ionized and were detected by an inline
mass spectrometer (Thermo Q Exactive). The spectra were collected first
(in0.5 s) and the top 20 abundant ions, or ions within predefinedmass ranges
(for targeted MS/MS), were sequentially isolated for MS/MS analysis (each in
0.1 s, totaling 2 s). This process (2.5 s) was cycled over the entire elution
chromatography gradient, acquiring more than 14,000 MS/MS spectra during
a 30min elution. Database searcheswere performed using the Sequest search
engine in the SPIDERS in-house software package. All matched MS/MS
spectra were filtered bymass accuracy andmatching scores to reduce protein
false discovery rate to less than 1%. The modification sites were determined
by dynamically assigning related mass addition to all possible amino acid res-
idues during database search. Modified residues were further validated by
manual examination of raw spectra and confirmed on the basis of the unam-
biguous assignment of characteristic site-specific fragment ions.
ACCESSION NUMBERS
Atomic coordinates and structure factors of mTBK1 in complex with BX795
and SU6668 have been deposited in the Protein Data Bank with accession
codes 4JL9 and 4JLC, respectively.
SUPPLEMENTAL INFORMATION
Supplemental Information includes seven figures and can be found with this
article online at http://dx.doi.org/10.1016/j.str.2013.04.025.
ACKNOWLEDGMENTS
The Berkeley Center for Structural Biology is supported in part by the National
Institutes of Health, National Institute of General Medical Sciences, and the
Howard Hughes Medical Institute. The Advanced Light Source is supported
by the Director, Office of Science, Office of Basic Energy Sciences, of the
U.S. Department of Energy under Contract No. DE-AC02-05CH11231. This
work was partially supported by ALSAC (American Lebanese Syrian Associ-
ated Charities grant to A.M.). We are grateful to Dr. Xiuren Zhang and
Dr. Ping He for their help with the protein kinase assays and Dr. Jun-yuan Ji
for critical reading of the manuscript. Research in the Li lab is supported by
NIH grant 1R01AI087741.
Received: February 28, 2013
Revised: April 19, 2013
Accepted: April 29, 2013
Published: June 6, 2013
REFERENCES
Adams, P.D., Afonine, P.V., Bunko´czi, G., Chen, V.B., Davis, I.W., Echols, N.,
Headd, J.J., Hung, L.W., Kapral, G.J., Grosse-Kunstleve, R.W., et al. (2010).
PHENIX: a comprehensive Python-based system for macromolecular struc-
ture solution. Acta Crystallogr. D Biol. Crystallogr. 66, 213–221.
Barber, G.N. (2011). Innate immune DNA sensing pathways: STING, AIMII and
the regulation of interferon production and inflammatory responses. Curr.
Opin. Immunol. 23, 10–20.
Barbie, D.A., Tamayo, P., Boehm, J.S., Kim, S.Y., Moody, S.E., Dunn, I.F.,
Schinzel, A.C., Sandy, P., Meylan, E., Scholl, C., et al. (2009). Systematic
RNA interference reveals that oncogenic KRAS-driven cancers require
TBK1. Nature 462, 108–112.
Brown, P.H., and Schuck, P. (2006). Macromolecular size-and-shape distribu-
tions by sedimentation velocity analytical ultracentrifugation. Biophys. J. 90,
4651–4661.
Bru¨nger, A.T., Adams, P.D., Clore, G.M., DeLano, W.L., Gros, P., Grosse-
Kunstleve, R.W., Jiang, J.S., Kuszewski, J., Nilges, M., Pannu, N.S., et al.
(1998). Crystallography & NMR system: a new software suite for macromolec-
ular structure determination. Acta Crystallogr. D Biol. Crystallogr. 54, 905–921.Structure 21, 1Burdette, D.L., and Vance, R.E. (2013). STING and the innate immune
response to nucleic acids in the cytosol. Nat. Immunol. 14, 19–26.
Cheng, G., and Baltimore, D. (1996). TANK, a co-inducer with TRAF2 of TNF-
and CD 40L-mediated NF-kB activation. Genes Dev. 10, 963–973.
Clark, K., Plater, L., Peggie,M., and Cohen, P. (2009). Use of the pharmacolog-
ical inhibitor BX795 to study the regulation and physiological roles of TBK1 and
IkB kinase ε: a distinct upstream kinase mediates Ser-172 phosphorylation
and activation. J. Biol. Chem. 284, 14136–14146.
Emsley, P., Lohkamp, B., Scott, W.G., and Cowtan, K. (2010). Features and
development of Coot. Acta Crystallogr. D Biol. Crystallogr. 66, 486–501.
Fitzgerald, K.A., McWhirter, S.M., Faia, K.L., Rowe, D.C., Latz, E., Golenbock,
D.T., Coyle, A.J., Liao, S.M., andManiatis, T. (2003). IKKε and TBK1 are essen-
tial components of the IRF3 signaling pathway. Nat. Immunol. 4, 491–496.
Fujii, K., Nakamura, S., Takahashi, K., and Inagaki, F. (2010). Systematic char-
acterization by mass spectrometric analysis of phosphorylation sites in IRF-3
regulatory domain activated by IKK-i. J. Proteomics 73, 1196–1203.
Godl, K., Gruss, O.J., Eickhoff, J., Wissing, J., Blencke, S., Weber, M., Degen,
H., Brehmer, D., Orfi, L., Horva´th, Z., et al. (2005). Proteomic characterization
of the angiogenesis inhibitor SU6668 reveals multiple impacts on cellular
kinase signaling. Cancer Res. 65, 6919–6926.
Goncalves, A., Bu¨rckstu¨mmer, T., Dixit, E., Scheicher, R., Go´rna, M.W.,
Karayel, E., Sugar, C., Stukalov, A., Berg, T., Kralovics, R., et al. (2011).
Functional dissection of the TBK1 molecular network. PLoS ONE 6, e23971.
Ha¨cker, H., and Karin, M. (2006). Regulation and function of IKK and IKK-
related kinases. Sci. STKE 2006, re13.
Helgason, E., Phung, Q.T., and Dueber, E.C. (2013). Recent insights into the
complexity of Tank-binding kinase 1 signaling networks: The emerging role
of cellular localization in the activation and substrate specificity of TBK1.
FEBS Lett. 587, 1230–1237.
Hemmi, H., Takeuchi, O., Sato, S., Yamamoto, M., Kaisho, T., Sanjo, H.,
Kawai, T., Hoshino, K., Takeda, K., and Akira, S. (2004). The roles of two IkB
kinase-related kinases in lipopolysaccharide and double stranded RNA
signaling and viral infection. J. Exp. Med. 199, 1641–1650.
Huang, Y.H., Liu, X.Y., Du, X.X., Jiang, Z.F., and Su, X.D. (2012). The structural
basis for the sensing and binding of cyclic di-GMP by STING. Nat. Struct. Mol.
Biol. 19, 728–730.
Jones, T.A., and Kjeldgaard, M. (1997). Electron-density map interpretation.
Methods Enzymol. 277, 173–208.
Kanai, F., Yoshida, H., Tateishi, R., Sato, S., Kawabe, T., Obi, S., Kondo, Y.,
Taniguchi, M., Tagawa, K., Ikeda, M., et al. (2011). A phase I/II trial of the
oral antiangiogenic agent TSU-68 in patients with advanced hepatocellular
carcinoma. Cancer Chemother. Pharmacol. 67, 315–324.
Kato, H., Takahasi, K., and Fujita, T. (2011). RIG-I-like receptors: cytoplasmic
sensors for non-self RNA. Immunol. Rev. 243, 91–98.
Kawai, T., Takahashi, K., Sato, S., Coban, C., Kumar, H., Kato, H., Ishii, K.J.,
Takeuchi, O., and Akira, S. (2005). IPS-1, an adaptor triggering RIG-I- and
Mda5-mediated type I interferon induction. Nat. Immunol. 6, 981–988.
Keating, S.E., Baran, M., and Bowie, A.G. (2011). Cytosolic DNA sensors regu-
lating type I interferon induction. Trends Immunol. 32, 574–581.
Larabi, A., Devos, J.M., Ng, S.L., Nanao, M.H., Round, A., Maniatis, T., and
Panne, D. (2013). Crystal structure and mechanism of activation of TANK-
binding kinase 1. Cell Rep. 3, 734–746.
Li, J., Li, J., Miyahira, A., Sun, J., Liu, Y., Cheng, G., and Liang, H. (2012).
Crystal structure of the ubiquitin-like domain of human TBK1. Protein Cell 3,
383–391.
Lin, R., Heylbroeck, C., Pitha, P.M., and Hiscott, J. (1998). Virus-dependent
phosphorylation of the IRF-3 transcription factor regulates nuclear transloca-
tion, transactivation potential, and proteasome-mediated degradation. Mol.
Cell. Biol. 18, 2986–2996.
Ma, X., Helgason, E., Phung, Q.T., Quan, C.L., Iyer, R.S., Lee, M.W., Bowman,
K.K., Starovasnik, M.A., and Dueber, E.C. (2012). Molecular basis of Tank-
binding kinase 1 activation by transautophosphorylation. Proc. Natl. Acad.
Sci. USA 109, 9378–9383.137–1148, July 2, 2013 ª2013 Elsevier Ltd All rights reserved 1147
Structure
Structure of TBK1Meylan, E., Curran, J., Hofmann, K., Moradpour, D., Binder, M.,
Bartenschlager, R., and Tschopp, J. (2005). Cardif is an adaptor protein in
the RIG-I antiviral pathway and is targeted by hepatitis C virus. Nature 437,
1167–1172.
Oshiumi, H., Matsumoto, M., Funami, K., Akazawa, T., and Seya, T. (2003).
TICAM-1, an adaptor molecule that participates in Toll-like receptor 3-medi-
ated interferon-b induction. Nat. Immunol. 4, 161–167.
Otwinowski, Z., and Minor, W. (1997). Processing of X-ray diffraction data
collected in oscillation mode. Methods Enzymol. 276, 307–326.
Ou, Y.H., Torres, M., Ram, R., Formstecher, E., Roland, C., Cheng, T.,
Brekken, R., Wurz, R., Tasker, A., Polverino, T., et al. (2011). TBK1 directly
engages Akt/PKB survival signaling to support oncogenic transformation.
Mol. Cell 41, 458–470.
Pilli, M., Arko-Mensah, J., Ponpuak, M., Roberts, E., Master, S., Mandell, M.A.,
Dupont, N., Ornatowski, W., Jiang, S., Bradfute, S.B., et al. (2012). TBK-1 pro-
motes autophagy-mediated antimicrobial defense by controlling autophago-
some maturation. Immunity 37, 223–234.
Seth, R.B., Sun, L., Ea, C.K., and Chen, Z.J. (2005). Identification and charac-
terization of MAVS, a mitochondrial antiviral signaling protein that activates
NF-kB and IRF 3. Cell 122, 669–682.
Sharma, S., tenOever, B.R., Grandvaux, N., Zhou, G.P., Lin, R., and Hiscott, J.
(2003). Triggering the interferon antiviral response through an IKK-related
pathway. Science 300, 1148–1151.
Shu, C., Yi, G., Watts, T., Kao, C.C., and Li, P. (2012). Structure of STING
bound to cyclic di-GMP reveals the mechanism of cyclic dinucleotide recogni-
tion by the immune system. Nat. Struct. Mol. Biol. 19, 722–724.
Suhara, W., Yoneyama, M., Iwamura, T., Yoshimura, S., Tamura, K., Namiki,
H., Aimoto, S., and Fujita, T. (2000). Analyses of virus-induced homomeric
and heteromeric protein associations between IRF-3 and coactivator
CBP/p300. J. Biochem. 128, 301–307.
Sun, L., Wu, J., Du, F., Chen, X., and Chen, Z.J. (2013). Cyclic GMP-AMP syn-
thase is a cytosolic DNA sensor that activates the type I interferon pathway.
Science 339, 786–791.
Takahasi, K., Horiuchi, M., Fujii, K., Nakamura, S., Noda, N.N., Yoneyama, M.,
Fujita, T., and Inagaki, F. (2010). Ser386 phosphorylation of transcription factor
IRF-3 induces dimerization and association with CBP/p300 without overall
conformational change. Genes Cells 15, 901–910.1148 Structure 21, 1137–1148, July 2, 2013 ª2013 Elsevier Ltd All rigTakeuchi, O., and Akira, S. (2009). Innate immunity to virus infection. Immunol.
Rev. 227, 75–86.
Takeuchi, O., and Akira, S. (2010). Pattern recognition receptors and inflam-
mation. Cell 140, 805–820.
Tu, D., Zhu, Z., Zhou, A.Y., Yun, C.H., Lee, K.E., Toms, A.V., Li, Y., Dunn, G.P.,
Chan, E., Thai, T., et al. (2013). Structure and ubiquitination-dependent activa-
tion of TANK-binding kinase 1. Cell Rep 3, 747–758.
Wild, P., Farhan, H., McEwan, D.G., Wagner, S., Rogov, V.V., Brady, N.R.,
Richter, B., Korac, J., Waidmann, O., Choudhary, C., et al. (2011).
Phosphorylation of the autophagy receptor optineurin restricts Salmonella
growth. Science 333, 228–233.
Winn, M.D., Ballard, C.C., Cowtan, K.D., Dodson, E.J., Emsley, P., Evans,
P.R., Keegan, R.M., Krissinel, E.B., Leslie, A.G., McCoy, A., et al. (2011).
Overview of the CCP4 suite and current developments. Acta Crystallogr. D
Biol. Crystallogr. 67, 235–242.
Wu, J., Sun, L., Chen, X., Du, F., Shi, H., Chen, C., and Chen, Z.J. (2013). Cyclic
GMP-AMP is an endogenous second messenger in innate immune signaling
by cytosolic DNA. Science 339, 826–830.
Xie, X., Zhang, D., Zhao, B., Lu, M.K., You, M., Condorelli, G., Wang, C.Y., and
Guan, K.L. (2011). IkB kinase ε and TANK-binding kinase 1 activate AKT by
direct phosphorylation. Proc. Natl. Acad. Sci. USA 108, 6474–6479.
Xu, G., Lo, Y.C., Li, Q., Napolitano, G., Wu, X., Jiang, X., Dreano, M., Karin, M.,
and Wu, H. (2011). Crystal structure of inhibitor of kB kinase b. Nature 472,
325–330.
Yamamoto, M., Sato, S., Hemmi, H., Hoshino, K., Kaisho, T., Sanjo, H.,
Takeuchi, O., Sugiyama, M., Okabe, M., Takeda, K., and Akira, S. (2003).
Role of adaptor TRIF in the MyD88-independent toll-like receptor signaling
pathway. Science 301, 640–643.
Yoneyama, M., Suhara, W., Fukuhara, Y., Fukuda, M., Nishida, E., and Fujita,
T. (1998). Direct triggering of the type I interferon system by virus infection:
activation of a transcription factor complex containing IRF-3 and CBP/p300.
EMBO J. 17, 1087–1095.
Yoneyama, M., Suhara, W., and Fujita, T. (2002). Control of IRF-3 activation by
phosphorylation. J. Interferon Cytokine Res. 22, 73–76.
Zheng, J., Trafny, E.A., Knighton, D.R., Xuong, N.H., Taylor, S.S., Ten Eyck,
L.F., and Sowadski, J.M. (1993). 2.2 A˚ refined crystal structure of the catalytic
subunit of cAMP-dependent protein kinase complexed with MnATP and a
peptide inhibitor. Acta Crystallogr. D Biol. Crystallogr. 49, 362–365.hts reserved
